AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8189562 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound (10 MHz color Doppler unit after intracorporeal pharmacological stimulation)
Number of subjects: 40
Study 8189562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal penile tumescence evaluation (measured at a sleep laboratory)
Number of subjects: 40
Study 8189562 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound
Number of subjects: 40
Study 8189562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal penile tumescence
Number of subjects: 40
Study 3099102 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 2 (rIL2)
Number of subjects: 10
Study 3099102 — intervention group
Group type: COMPARATOR
Intervention: Phytohemagglutinin
Number of subjects: 10
Study 31634194 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART (EAAA)
Number of subjects: 2629
Study 31634194 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed ART)
Number of subjects: 2629
Study 31117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial anti-tachycardia pacing (A‐ATP) from a Medtronic dual‐chamber pacemaker
Number of subjects: 0
Study 31117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial anti-tachycardia pacing (A‐ATP)
Number of subjects: 0
Study 28156130 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermoSuit (TS)
Number of subjects: 22
Study 28156130 — intervention group
Group type: EXPERIMENTAL
Intervention: EMCOOLS Flex.Pad (EC)
Number of subjects: 22
Study 28156130 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-cooling unit (BCU)
Number of subjects: 22
Study 28156130 — intervention group
Group type: COMPARATOR
Intervention: No cooling (CON)
Number of subjects: 22
Study 25311594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive voice therapy
Number of subjects: 53
Study 25311594 — intervention group
Group type: COMPARATOR
Intervention: Traditional voice therapy
Number of subjects: 53
Study 23657728 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided management
Number of subjects: 123
Study 23657728 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided management
Number of subjects: 123
Study 21384174 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1158
Study 21384174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1158
Study 19117884 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive hemoglobin transfusion threshold
Number of subjects: 451
Study 19117884 — intervention group
Group type: COMPARATOR
Intervention: Liberal hemoglobin transfusion threshold
Number of subjects: 451
Study 17088509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 0
Study 14702268 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg)
Number of subjects: 0
Study 14702268 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection (measured by IgG and IgA antibodies) in CAD patients with CRF
Number of subjects: 214
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection (measured by IgG and IgA antibodies) in all CAD patients
Number of subjects: 214
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean antibody index of IgG in CAD patients
Number of subjects: 214
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of IgG in CAD patients
Number of subjects: 214
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA levels in CAD patients with CRF
Number of subjects: 214
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IgG antibody index
Number of subjects: 214
Study 11758004 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IgA index
Number of subjects: 214
Study 9158267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyrelle 50
Number of subjects: 394
Study 9158267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyrelle 80
Number of subjects: 394
Study 9158267 — intervention group
Group type: COMPARATOR
Intervention: Estraderm TTS 50
Number of subjects: 394
Study 9158267 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Lyrelle 50, Lyrelle 80, Estraderm TTS 50)
Number of subjects: 394
Study 7951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in NGT subjects (n = 13)
Number of subjects: 37
Study 7951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in BGI subjects (n = 12)
Number of subjects: 37
Study 7951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in NIDDM subjects (n = 12)
Number of subjects: 37
Study 3661614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g twice daily
Number of subjects: 50
Study 3661614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29511780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 18
Study 26604097 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo educational intervention
Number of subjects: 0
Study 26604097 — intervention group
Group type: COMPARATOR
Intervention: Active control education
Number of subjects: 0
Study 25500097 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record (IPHR)
Number of subjects: 40
Study 25500097 — intervention group
Group type: COMPARATOR
Intervention: Traditional Personal Health Records (PHRs)
Number of subjects: 40
Study 22850577 — intervention group
Group type: EXPERIMENTAL
Intervention: Triaxial system
Number of subjects: 63
Study 22850577 — intervention group
Group type: COMPARATOR
Intervention: Conventional system (control group)
Number of subjects: 63
Study 20335136 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized stroke ward
Number of subjects: 2637
Study 20335136 — intervention group
Group type: COMPARATOR
Intervention: General ward
Number of subjects: 2637
Study 18725822 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider intervention featuring academic detailing and strategic planning session
Number of subjects: 2224
Study 18725822 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2224
Study 18725822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 2224
Study 15982990 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg G115
Number of subjects: 30
Study 15982990 — intervention group
Group type: EXPERIMENTAL
Intervention: 400mg G115
Number of subjects: 30
Study 15982990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12074223 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow flow rate (161 sec/mL) of 0.3 mL local anesthetic solution
Number of subjects: 20
Study 12074223 — intervention group
Group type: COMPARATOR
Intervention: Fast flow rate (29 sec/mL) of 0.3 mL local anesthetic solution
Number of subjects: 20
Study 12074223 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate as a physiologic indicator of pain response
Number of subjects: 20
Study 9605697 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (FAW)
Number of subjects: 100
Study 9605697 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal care
Number of subjects: 100
Study 8083715 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loading consolidation therapy (6 MTX/Ara-C infusions at 3-week intervals from 7th to 19th week)
Number of subjects: 428
Study 8083715 — intervention group
Group type: COMPARATOR
Intervention: Standard consolidation therapy (6 MTX/Ara-C infusions every 12 weeks from 7th to 67th week)
Number of subjects: 428
Study 8083715 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loading regimen
Number of subjects: 428
Study 8083715 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 428
Study 2671408 — intervention group
Group type: EXPERIMENTAL
Intervention: Well matched cadaver renal allografts shared among transplantation centers
Number of subjects: 0
Study 2671408 — intervention group
Group type: COMPARATOR
Intervention: Organs of local origin matched only for blood group
Number of subjects: 0
Study 146411 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachlorophenylalanine and testosterone
Number of subjects: 0
Study 146411 — intervention group
Group type: COMPARATOR
Intervention: Parachlorophenylalanine
Number of subjects: 0
Study 146411 — intervention group
Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 0
Study 146411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 146411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 0
Study 30383672 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginary Working Qigong training for 8 weeks
Number of subjects: 80
Study 30383672 — intervention group
Group type: COMPARATOR
Intervention: Unaltered lifestyle control group
Number of subjects: 80
Study 27381831 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Capecitabine and Oxaliplatin (CAPOX)
Number of subjects: 155
Study 27381831 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant Capecitabine and Oxaliplatin (CAPOX) + Cetuximab (CAPOX-C)
Number of subjects: 155
Study 24724577 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0
Study 24724577 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction for coagulation factors
Number of subjects: 0
Study 22304627 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg of r-hCG
Number of subjects: 118
Study 22304627 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg of r-hCG
Number of subjects: 118
Study 22304627 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 118
Study 19604542 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/day clopidogrel
Number of subjects: 54
Study 19604542 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day clopidogrel
Number of subjects: 54
Study 18756184 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of oral pentavalent rotavirus vaccine (PRV) and oral poliovirus vaccine (OPV)
Number of subjects: 735
Study 18756184 — intervention group
Group type: COMPARATOR
Intervention: Staggered use of PRV 2-4 weeks before OPV
Number of subjects: 735
Study 18756184 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of PRV and OPV
Number of subjects: 735
Study 15715552 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof MA30BA
Number of subjects: 175
Study 15715552 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40e
Number of subjects: 175
Study 15715552 — intervention group
Group type: COMPARATOR
Intervention: AcrySof SA30AL
Number of subjects: 175
Study 15715552 — intervention group
Group type: COMPARATOR
Intervention: Tecnis Z9000
Number of subjects: 175
Study 15715552 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40
Number of subjects: 175
Study 12675275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg
Number of subjects: 46
Study 12675275 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 46
Study 11276181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior mobilization on the talus in addition to RICE protocol
Number of subjects: 41
Study 11276181 — intervention group
Group type: COMPARATOR
Intervention: RICE protocol
Number of subjects: 41
Study 9097267 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha 2b (1.5 MU, increasing to 3 MU if no response)
Number of subjects: 23
Study 9097267 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 23
Study 1371633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg p.o.
Number of subjects: 60
Study 1371633 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 60
Study 1371633 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.01 mg/kg i.m.
Number of subjects: 60
Study 1371633 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 60
Study 3873866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 81
Study 3873866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 28735763 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 62
Study 28735763 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP treatment)
Number of subjects: 62
Study 28735763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 29332637 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-oriented multicomponent group therapy (12 sessions of 90 minutes each) integrating interactive psychoeducation, gut-directed hypnotherapy, and open group phases.
Number of subjects: 30
Study 29332637 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control condition with enhanced medical care and a short online diary.
Number of subjects: 30
Study 26625419 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Catching
Number of subjects: 41
Study 26625419 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Catching
Number of subjects: 41
Study 26625419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptive Catching
Number of subjects: 41
Study 26625419 — intervention group
Group type: COMPARATOR
Intervention: Control (Mario game)
Number of subjects: 41
Study 23404659 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention (Focus on Families project)
Number of subjects: 151
Study 23404659 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 151
Study 22972960 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with visual demonstration and robotic assistance
Number of subjects: 0
Study 22972960 — intervention group
Group type: COMPARATOR
Intervention: Visual demonstration alone (Control)
Number of subjects: 0
Study 22972960 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive guidance during active movement (Additional Control)
Number of subjects: 0
Study 20410466 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy-based oncology RCTs
Number of subjects: 262
Study 17645811 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study 17645811 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 0
Study 16162039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dissemination materials plus 2 brief follow‐up phone calls (tailored group)
Number of subjects: 126
Study 16162039 — intervention group
Group type: COMPARATOR
Intervention: Generic materials (basic group)
Number of subjects: 126
Study 11575897 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler 4.5 microg)
Number of subjects: 362
Study 11575897 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (Bricanyl Turbuhaler 0.5 mg)
Number of subjects: 362
Study 9272401 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (3 x 6 mg per day)
Number of subjects: 10
Study 9272401 — intervention group
Group type: COMPARATOR
Intervention: Anetholtrithione (3 x 25 mg per day)
Number of subjects: 10
Study 7942085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with estradiol and estradiol plus medroxyprogesterone acetate
Number of subjects: 15
Study 7942085 — intervention group
Group type: COMPARATOR
Intervention: Amenorrheic patients
Number of subjects: 15
Study 7942085 — intervention group
Group type: COMPARATOR
Intervention: Normally cycling women (control group)
Number of subjects: 15
Study 3367488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendehill rubella virus vaccine
Number of subjects: 1290
Study 3367488 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐77 DE‐5 rubella virus vaccine
Number of subjects: 1290
Study 3367488 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐77 DK‐12 rubella virus vaccine
Number of subjects: 1290
Study 1957903 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol 0.5%
Number of subjects: 40
Study 1957903 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 40
Study 56908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epontol (7 mg/kg i.v.)
Number of subjects: 0
Study 56908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injection of Epontol (7 mg/kg) and infusion (21 mg/kg during 15 min)
Number of subjects: 0
Study 56908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injection of Epontol (7 mg/kg) and suxamethonium (0.5 mg/kg)
Number of subjects: 0
Study 56908 — intervention group
Group type: COMPARATOR
Intervention: Anaesthesia with ketamine (Ketanest), halothane or nitrous oxide
Number of subjects: 0
Study 31987540 — intervention group
Group type: EXPERIMENTAL
Intervention: True Qigong
Number of subjects: 66
Study 31987540 — intervention group
Group type: COMPARATOR
Intervention: Sham Qigong (Control)
Number of subjects: 66
Study 31987540 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting list group
Number of subjects: 66
Study 31893588 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-infused vitrectomy
Number of subjects: 42
Study 31893588 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional balanced salt solution-infused technique)
Number of subjects: 42
Study 31893588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 28099193 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation (PNS)
Number of subjects: 25
Study 28099193 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 25
Study 25365122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Enhanced Strengthening Families Program (MSFP)
Number of subjects: 432
Study 25365122 — intervention group
Group type: COMPARATOR
Intervention: Standard Strengthening Families Program (SFP 10-14)
Number of subjects: 432
Study 25365122 — intervention group
Group type: COMPARATOR
Intervention: Minimal-treatment home study control condition
Number of subjects: 432
Study 23057434 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (5 mL)
Number of subjects: 123
Study 23057434 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (25% glucose water, 5 mL)
Number of subjects: 123
Study 23057434 — intervention group
Group type: COMPARATOR
Intervention: Water (5 mL distilled water)
Number of subjects: 123
Study 21665265 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor (GPI)
Number of subjects: 1802
Study 21665265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 1802
Study 21665265 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1802
Study 21665265 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1802
Study 19659617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI) with therapeutic INR (mean INR 2.8 +/- 0.7)
Number of subjects: 194
Study 19659617 — intervention group
Group type: COMPARATOR
Intervention: Normal INR (mean INR 1.4 +/- 0.3)
Number of subjects: 194
Study 19659617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of major and minor complications
Number of subjects: 194
Study 16912354 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous extralesional triamcinolone acetonide injection (0.3 mL, 10 mg/mL)
Number of subjects: 28
Study 16912354 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (lid hygiene, warm compresses, chloramphenicol 1% ointment 4 times a day)
Number of subjects: 28
Study 16912354 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous extralesional triamcinolone acetonide injection
Number of subjects: 28
Study 16912354 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 28
Study 14755153 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics in capsules
Number of subjects: 35
Study 14755153 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics in liquid form
Number of subjects: 35
Study 14755153 — intervention group
Group type: COMPARATOR
Intervention: Placebo in both forms
Number of subjects: 35
Study 11985972 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis group (2 g of cephtazidime intravenously 30 minutes before ERCP)
Number of subjects: 321
Study 11985972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 321
Study 9271042 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV vaccine
Number of subjects: 145
Study 9271042 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV and Hib vaccine (mixed)
Number of subjects: 145
Study 9271042 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV and Hib vaccine (separate)
Number of subjects: 145
Study 9271042 — intervention group
Group type: COMPARATOR
Intervention: DTPw-IPV-Hib vaccine
Number of subjects: 145
Study 7935634 — intervention group
Group type: COMPARATOR
Intervention: Immediate fluid resuscitation
Number of subjects: 598
Study 7935634 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed fluid resuscitation
Number of subjects: 598
Study 3366075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fenoterol (bolus injection and continuous infusion)
Number of subjects: 8
Study 3366075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fenoterol
Number of subjects: 8
Study 3366075 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous and continuous intravenous administration of fenoterol and theophylline
Number of subjects: 8
Study 30158215 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D intervention
Number of subjects: 5253
Study 30158215 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 5253
Study 27862464 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 60
Study 27862464 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 60
Study 27862464 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional independence (mRS 0-2) with Imatinib
Number of subjects: 60
Study 27862464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60